Denali Therapeutics (DNLI) Leases: 2019-2025
Historic Leases for Denali Therapeutics (DNLI) over the last 7 years, with Sep 2025 value amounting to $49.4 million.
- Denali Therapeutics' Leases rose 27.82% to $49.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year increase of 27.82%. This contributed to the annual value of $47.5 million for FY2024, which is 82.48% up from last year.
- As of Q3 2025, Denali Therapeutics' Leases stood at $49.4 million, which was up 4.32% from $47.4 million recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Leases ranged from a high of $50.2 million in Q1 2025 and a low of $24.5 million during Q2 2024.
- Moreover, its 3-year median value for Leases was $28.0 million (2023), whereas its average is $35.6 million.
- Per our database at Business Quant, Denali Therapeutics' Leases fell by 14.46% in 2023 and then spiked by 98.34% in 2025.
- Denali Therapeutics' Leases (Quarterly) stood at $30.7 million in 2021, then dropped by 1.00% to $30.4 million in 2022, then declined by 14.42% to $26.0 million in 2023, then surged by 82.48% to $47.5 million in 2024, then grew by 27.82% to $49.4 million in 2025.
- Its Leases was $49.4 million in Q3 2025, compared to $47.4 million in Q2 2025 and $50.2 million in Q1 2025.